A new and exciting member benefit is here! SITC is now accepting applications from members who would like to start a Special Interest Group (SIG). Joining a #SITCSIG will give you the opportunity to connect, contribute, and advance scientific issues. Learn more: sitcancer.org/sig

Three weeks left to apply for the NCI Immunotherapy Fellowship. Discover a variety of clinical cancer immunotherapy approaches through this visiting fellowship experience. Applications are due Aug. 18. Apply here: https://sitcancer.org/nci-immunotherapy-fellowship #Fellowship #IO #SITC

Hear from Pedro Romero, MD, about Biomarkers in Radioimmunotherapy at the 2026 SITC EU Immuno-Oncology Drug Development Summit and explore emerging strategies shaping the field. Register today: sitcancer.org/edu/edu-sitc-biotech-initiative/eu-io-summit

Submit Late-Breaking Abstracts – Clinical Only that highlight novel and practice-changing clinical studies for #SITC26. LBA submission deadline is Sept. 10. Additional oral presentation opportunities available! www.sitcancer.org/2026/abstract-lba OncoDaily

Discover how radioimmunotherapy is shaping the next wave of cancer immunotherapy. Join Ken Herrmann, MD, MBA, for a featured session at the 2026 SITC EU Immuno-Oncology Drug Development Summit. Register today: sitcancer.org/edu/edu-sitc-biotech-initiative/eu-io-summit

What's next for antibody-drug conjugates? Join the expert panel in Session III: Novel Modality – Antibody-drug Conjugates at the 2026 SITC EU Immuno-Oncology Drug Development Summit and hear where the field is headed. Register today: sitcancer.org/edu/edu-sitc-biotech-initiative/eu-io-summit

Register for our 41st Annual Meeting and Pre-Conference Programs. #SITC26 consists of cutting-edge research presentations by experts in the field, oral & poster abstract presentations & ample networking opportunities. Register now: https://www.sitcancer.org/2026/home

New collaboration: SITC & Cancer Research Institute bring the CRI William B. Coley Award Lecture to #SITC26. NK cell pioneer Éric Vivier, DVM, PhD delivers the inaugural lecture on harnessing NK cells in cancer therapy. Nov 4–8, Phoenix. sitcancer.org/2026 OncoDaily

Thanks to today's moderators, panelists, speakers, & attendees for making the inaugural IO-ACT Summit a success. Today's convos reinforced the value of bringing 2gether experts to tackle shared scientific and clinical challenges & identify opptys to advance PD-1×VEGF therapies.

#IOACT convo continues w/ panels on platform trial models & toxicity characterization—2 key areas for advancing efficient clinical dev. while ensuring patient safety. From trial infra. to AEM, the discussions emphasize the importance of rigorous evidence generation & innovation.

Thank you to Daina Graybosch, PhD (Leerink Partners) for sharing insights on the state-of-the-field for PD-1×VEGF combinations and the evolving clinical landscape.

We're kicking off the inaugural IO-ACT Summit today in Bethesda, bringing together experts from academia, industry, regulatory agencies, and patient advocacy to discuss opportunities and challenges surrounding PD-1×VEGF therapies. Follow along throughout the day for key insights!

See how ADC-IO combinations are reshaping urothelial cancer treatment at the 2026 SITC EU Immuno-Oncology Drug Development Summit. Don't miss this featured session. Register today: https://www.sitcancer.org/edu/edu-sitc-biotech-initiative/eu-io-summit

#Renew your SITC membership today to utilize all the benefits that come with it and stay current with the world’s leading member-driven organization solely dedicated to cancer #immunotherapy! https://www.sitcancer.org/renew

Share how much you love SITC! Make sure to use the Connect-a-Colleague Tool to let your colleagues know how to join the SITC family. The top referrer will be recognized at #SITC26 sitcancer.org/connect-a-colleague

Join leading experts as they identify new approaches to overcoming dominant mechanisms of resistance during the cutting-edge session, "IO in Low Mutation Burden Cancers", Nov. 7 at #SITC26 in Phoenix, AZ. View the session agenda: https://ow.ly/G4Ex50ZnTu4 OncoDaily

Celebrate 41 years of advancing IO at SITC 2026 held in Phoenix, AZ on Nov. 4–8. #SITC26 will bring together leaders for unmatched education, scientific exchange & networking with the scientists driving the field. Attend virtually or in-person! https://www.sitcancer.org/2026/home

Late-Breaking Abstracts – Clinical Only (LBAs) submissions are now open! LBA submission is solely for abstracts with late-breaking data from interventional clinical trials in humans. Submit by Sept. 10. Additional oral presentation opportunities available! www.sitcancer.org/2026/abstract-lba

Happening tomorrow! Don't miss Webinar 2 of the Targets for Cancer IO: A Deep Dive series. Explore the latest advances in IO for MSS colon cancer with leading experts. Register now: https://www.sitcancer.org/edu/webinars/targets-for-cancer-io

From novel targets to next-generation therapeutics, discover what's advancing cancer drug development. Join Michael Alonso, PhD, for BDC-4182: A Claudin 18.2-Targeting ISAC at the SITC EU Immuno-Oncology Drug Development Summit. Register: sitcancer.org/edu/edu-sitc-biotech-initiative/eu-io-summit

New #JITC article: "Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1–NLRC5–MHC-I axis in urothelial carcinoma" jitc.bmj.com/content/14/7...

Join JACI 2026 and address relevant trends such as IO resistance and personalized cancer IO with leading experts! Organized in collaboration with SITC, this meeting is held July 22–24, in Kagawa, Japan or virtual. View more: https://ow.ly/L0E750Z2f3V OncoDaily

Join the Panel Discussion: Pre-Clinical Models at the 2026 SITC EU Immuno-Oncology Drug Development Summit to gain insight from industry leaders on what’s working—and what’s changing—in translational research. Register today: https://www.sitcancer.org/edu/edu-sitc-biotech-initiative/eu-io-summit

New #JITC article: "Emergence of a mixed CAF population by FAP-CD3 T-cell engager limits therapeutic efficacy" jitc.bmj.com/content/14/7... 🧪

Discover the latest advances in IO for GI cancers and earn free CME! Join clinical expert during SITC’s ACI: A Focus on Gastrointestinal Cancers program Sept. 9 to access expert insights on the most recent clinical data. Learn more: https://www.sitcancer.org/edu/aci/gastro-cancers

Register now for Webinar 2 of the Targets for Cancer IO: A Deep Dive series. Gain practical insights into emerging immunotherapy strategies for MSS Colon Cancer and the science driving future advances. https://www.sitcancer.org/edu/webinars/targets-for-cancer-io

Emerging targets are shaping the future of immuno-oncology. Join Alessandra Curioni-Fontecedro, MD, for B7-H3 (CD276) in Cancer at the 2026 SITC EU Immuno-Oncology Drug Development Summit. Register today: https://www.sitcancer.org/edu/edu-sitc-biotech-initiative/eu-io-summit

We’re excited to announce the NCI Immunotherapy Fellowship! This one-year program offers training in clinical trial design, protocol development, patient care, toxicity management and more. Applications are due Aug. 18. https://sitcancer.org/nci-immunotherapy-fellowship #Fellowship #IO #SITC

New #JITC article: "Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release" jitc.bmj.com/content/14/6... 🧪

New review: "Emerging role of microRNAs as modulators of the tumor immune microenvironment" jitc.bmj.com/content/14/6...